Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists | Science

The relaxin receptor RXFP1 is a therapeutic target owing to its potential benefits in the treatment of fibrosis and heart failure. Protein and small-molecule agonists are currently in midstage clinical trials for various forms of heart disease. In this ...
Newsletter
Get the latest news delivered to your inbox.
Related articles





